GET DAILY SIGNALSWhy Is Krystal Biotech (KRYS) Stock Down -8.82% Today?
Key Takeaways
- KRYS shares fell 8.82% to $302.98, down $29.31 from the prior close of $332.29.
- The decline came despite a third-quarter earnings beat, with the sell-off driven by pushed-back pipeline timelines.
- Management disclosed delays across multiple programs, including KB801, KB407, and KB304.
- Net income declined year over year, pressured by an income tax expense versus a prior-year tax benefit.
- A newly authorized $400 million share repurchase program provided a partial offset but failed to stem the slide.
- For deeper detail, explore Price Targets, Earnings, and Forecast pages on Tickeron.
- Interested in automated trading strategies? Discover Trending AI Robots to see how AI-driven bots approach tickers like this one.
Opening Summary
Krystal Biotech, Inc. (KRYS), a commercial-stage biotechnology company best known for its VYJUVEK gene therapy for dystrophic epidermolysis bullosa, saw its shares plunge in Monday's session despite reporting better-than-expected third-quarter results. The stock traded at $302.98, down 8.82% from Friday's close of $332.29. The immediate market reaction reflected investor disappointment over delayed clinical timelines that overshadowed an otherwise solid top- and bottom-line beat.
Earnings Beat Overshadowed by Pipeline Delays
Krystal Biotech reported third-quarter adjusted earnings of $2.05 per share, exceeding the consensus estimate of $1.84, while product revenue of $127.34 million rose 30% year over year and topped expectations. Gross margin remained exceptional at 94%, and the company ended the quarter with roughly $1.2 billion in cash and investments. Yet the shares sold off sharply, a sign that traders were focused on the company's forward-looking disclosures rather than the headline numbers.
The pivotal concern was a series of timeline shifts across the clinical pipeline. Management acknowledged that enrollment in the EMERALD-1 study of KB801 for neurotrophic keratitis has progressed slower than anticipated, pushing top-line results into 2027. Interim results for KB407 in cystic fibrosis were moved to the first half of 2027, and KB304 in aesthetics is no longer expected to enter Phase 2 until 2027. Because the company's valuation increasingly depends on converting VYJUVEK cash flow into a diversified product portfolio, these delays weighed heavily on sentiment.
Declining Profitability and Tax Headwinds
Beyond the timeline slippage, the quarter's profitability optics were less favorable than a year ago. Net income fell to $63.1 million, or $2.13 per basic share, from $79.4 million in the prior-year period. The decline was driven in part by a $17.08 million income tax expense, compared with a $31.40 million income tax benefit recorded a year earlier. While the company reiterated full-year guidance for adjusted combined R&D and SG&A expenses, the year-over-year profit compression gave investors a further reason to lock in gains after a strong run.
Institutional Positioning and Profit-Taking
The sell-off also followed signs of shifting institutional ownership. A recent regulatory filing showed Vanguard reduced its stake below the 5% threshold, a move that can weigh on a stock's liquidity and dampen investor confidence. Combined with a multi-day pullback in the shares leading into the report, the earnings event provided a catalyst for accelerated profit-taking among traders who had enjoyed substantial gains earlier in the year.
Market Context and Trading Activity
Trading in KRYS was notably active throughout the morning, with volume running at an elevated pace versus the stock's typical daily turnover. The decline extended a recent stretch of softness that had already left the stock trading below its 20-day moving average. The move pushed shares toward the lower end of their recent trading range, a technically significant breakdown that likely triggered additional selling from momentum-oriented traders. The downturn was largely company-specific, reflecting the pipeline disclosures rather than a broader retreat across the biotechnology sector.
What Comes Next for KRYS
Looking ahead, investors will be watching execution on VYJUVEK's continued U.S. growth and international expansion, including pricing negotiations in multiple European markets and an anticipated Italian launch in early 2027. Key clinical milestones—including the Hailey-Hailey readout, KB407 interim data in the first half of 2027, and the KB801 top-line results—will be central to the stock's path. The newly authorized $400 million buyback could provide some support, but risks remain, including slower-than-expected trial enrollment, regulatory uncertainty, and the inherent volatility of biotech valuations tied to pipeline news.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are among the strongest performers under current market conditions. Tickeron offers hundreds of bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Exploring this section can help traders see how automated systems are navigating moves like today's. Visit Trending AI Robots to learn more.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
KRYS sees its Stochastic Oscillator recovers from oversold territory
On October 28, 2026, the Stochastic Oscillator for KRYS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 45 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 259 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 83 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 42 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
KRYS moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for KRYS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.444) is normal, around the industry mean (3.104). P/E Ratio (35.780) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company which provides therapies for rare and orphan diseases
Industry Biotechnology
Advertisement